Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a mid-atlantic oncology program study

Journal of Clinical Oncology

Volumn 9, Issue 8, 1991, Pages 1438-1445

  Wampler, Galen L ^a,f   Heim, William J ^b   Ellison, Neil M ^c   Ahlgren, James D ^d   Fryer, John G ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Hematol Oncol Assoc NE P ^*  (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; VINCRISTINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE; VINCRISTINE;

EID: 0025887856     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1991.9.8.1438     Document Type: Article

References (31)

1. Goldie JH, Goldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
2. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
3. Wampler GL, Carter WH Jr, Campbell ED, et al: Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia. Cancer Treat Rep 71:581-591, 1987
4. Zubrod CG, Schneiderman M, Frei E III, et al: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11:7-33, 1960
5. Maurer LM, Pajak TF: Prognostic factors in small cell carcinoma of the lung: A Cancer and Leukemia Group B study. Cancer Treat Rep 65:767-774, 1981
6. Idhe DC, Makuch RW, Carney DN, et al: Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 123:500-507, 1981
7. Zimm S, Wampler GL, Stablein D, et al: Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 48:384-394, 1981
8. Ajani JA, Welch SR, Raber MN: Comprehensive criteria for assessing therapy-related toxicity. Cancer Invest 8:141-153, 1990
9. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Arm Intern Med 107:451-458, 1987
10. Johnson BE, Steinberg SM, Phelps R, et al: Female patients with small cell lung cancer live longer than male patients. Am J Med 85:194-196, 1988
11. Lurie S, Morgan T, Jackson DV: Prognostic factors in small cell carcinoma of the lung. Proc Am Soc Clin Oncol 5:177, 1986 (abstr)
12. Ettinger DS, Finkelstein DM, Abeloff MD, et al: A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-disease small-cell lung cancer: A Phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8:230-240, 1990
13. Souhami RL, Bradbury I, Geddes DM, et al: Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 45:2878-2882, 1985
14. Rawson NSP, Peto J: An overview of prognostic factors in small cell lung cancer. Br J Cancer 61:597-604, 1990
15. Larsson S: Pretreatment classification and staging of bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 7:44-56, 1973 (suppl 10)
16. Reinila A, Dammert K: An attempt to use the WHO typing in the histologic classification of lung carcinomas. Acta Pathol Microbiol Scand 82A:783-790, 1974
17. Hansen HH, Dombernowsky P, Hansen M, et al: Chemotherapy of advanced small-cell anaplastic carcinoma: Superiority of a four-drug combination to a three-drug combination. Ann Intern Med 89:177-181, 1978
18. Burdon JGW, Sinclair RA, Henderson MM: Small cell carcinoma of the lung: Prognosis in relation to histologic subtype. Chest 76:302-304, 1979
19. Matthews MJ, Gazdar AF: Pathology of small cell carcinoma of the lung and its subtypes: A clinico-pathologic correlation, in Livingston RB (ed): Lung Cancer I. The Hague, Netherlands, Martinus Nijhoff, 1981, pp 283-306
20. Vollmer RT, Birch R, Ogden L, et al: Subclassification of small cell cancer of the lung: The Southeastern Cancer Study Group experience. Hum Pathol 16:247-252, 1985
21. Feld R, Evans WK, Coy P, et al: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross resistant chemotherapy combinations in patients with limited small cell carcinoma of the lung. J Clin Oncol 5:1401-1409, 1987
22. Østerlind K, Hansen HH. Hansen M, et al: Long-term disease-free survival in small cell carcinoma of the lung: A study of clinical determinants. J Clin Oncol 4:1307-1313, 1986
23. Minna JD, Pass H, Glatstein E. et al: Cancer of the lung, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practices of Oncology. Philadelphia. PA. Lippincott, 1989, pp 591-705
24. Aisner SC, Finkelstein DM. Ettinger DS, et al: The clinical significance of variant-morphology small-cell carcinoma of the lung. J Clin Oncol 8:402-408, 1990
25. Aisner J, Whitacre M, Van Echo DA, et al: Combination chemotherapy for small cell carcinoma of the lung: Continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 66:221-230, 1982
26. Østerlind K, Sorenson S, Hansen HH, et al: Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 43:6085-6089, 1983
27. Livingston RB, Mira JG, Chen TT, et al: Combined modality treatment of extensive small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 2:585-590, 1984
28. Daniels JR, Chak LY, Sikic BI, et al: Chemotherapy of small-cell carcinoma of the lung: A randomized comparison of alternating and sequential chemotherapy programs. J Clin Oncol 2:1192-1199, 1984
29. Eagan RT, Frytak S, Creagan ET, et al: Continuous five-drug versus alternating three-drug and two-drug chemotherapy after five-drug or three-drug induction in extensive small cell lung cancer. Cancer Invest 3:299-305, 1985
30. Havemann K, Wolf M, Holle R, et al: Alternating versus sequential chemotherapy in small cell lung cancer: A randomized German multicenter trial. Cancer 59:1072-1082, 1987
31. Goodman GE, Crowley JJ, Blasko JC, et al: Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy. A Southwest Oncology Group study. J Clin Oncol 8:39-47, 1990